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Abstract: BG-4 isolated from bitter gourd has been reported for anti-cancer properties. The objective
was to evaluate the anti-inflammatory properties of BG-4 in vitro and in vivo. Comparative study of
the anti-inflammatory properties of BG-4 in vitro and in vivo was conducted on lipopolysaccharide
(LPS)-activated mouse macrophages, and on dextran sodium sulfate (DSS)-induced colitis in mice.
BG-4 reduced the production of pro-inflammatory markers in LPS-activated macrophages. On the
other hand, intraperitoneal administration of BG-4 in DSS-induced colitis led to colon shortening,
elevated neutrophils infiltration and myeloperoxidase activity, presence of blood in the stool, and loss
of body weight, with differential systemic and local effects on pro-inflammatory cytokines in vivo.
The results demonstrated that BG-4 differentially affected inflammation in vitro and in vivo.
Keywords: BG-4; bitter gourd; colitis; inflammation; macrophages

1. Introduction
Inflammatory bowel disease (IBD) is a life-long condition of chronic and relapsing inflammation of
the gastrointestinal tract associated with immune-mediated disorders [1]. It has two major phenotypes:
Crohn’s disease, which can severely affect any part of the bowel, and ulcerative colitis (UC), which
involves damage in the superficial mucosa of the colon, starting always from the anus [1,2]. IBD patients
are at major risk of developing gastrointestinal and extra-intestinal carcinomas, especially those carrying
UC whose probability for developing colitis-associated colorectal cancer (CACC) increases with the
length and severity of inflammatory manifestation [3]. The increasing incidence of UC, especially at a
younger age, has raised a global concern considering the detrimental consequences in terms of quality
of life, economic loss associated with lower productivity and increased medical expenses, and the
imminent risk of development of CACC [2,4]. Hence, alternative ways to manage inflammation are
needed, and plant origin compounds may prevent, ameliorate and alleviate chronic inflammation, and
consequently the risk of IBD and associated diseases.
Momordica charantia, commonly known as bitter gourd, is a member of the Cucurbitaceae family
mainly cultivated in Asia, Africa, and South America [5]. It is traditionally consumed as a vegetable and
with medicinal purposes such as treatment of inflammation, fever, rheumatism, as well as antidiabetic
and anti-helmitic [6]. Several studies have addressed in vitro and/or in vivo effects of the whole edible
parts or extracts with demonstrated anti-oxidant, anti-inflammatory, anti-diabetic, anti-cancer and
metabolic regulatory properties [7–12].
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BG-4 is a novel 4 kDa peptide isolated from bitter gourd seeds with trypsin inhibitory and
in vitro anti-colon cancer and anti-inflammatory properties [13,14]. BG-4 was isolated from the seeds
of Momordica charantia by 70% ethanol extraction. It showed very strong trypsin inhibitory activity
which is at least 8x more potent than purified soybean Kunitz trypsin inhibitor [13]. Moreover,
mass spectrometric analysis showed the following peptide sequence matches: SWPQLVGSTGAAAK,
VGSPVTADFR, GIVARPPAIG and DSDCLAQCICVDGHCG [13]. However, the potential bioactive
properties of BG-4 in animal models remain unexplored. Herein, we made a comparative in vitro and
in vivo anti-inflammatory study of BG-4, by measuring the expression of pro-inflammatory markers
in lipopolysaccharide (LPS)-activated mouse-derived macrophages, and in dextran sodium sulfate
(DSS)-induced colitis in mice. Our results indicate that BG-4 has differential effects in inflammation
within in vitro and in vivo settings.
2. Materials and Methods
2.1. Extraction of BG-4
The 4 kDa peptide BG-4 was extracted from bitter gourd seeds as described previously [13].
2.2. In Vitro Antioxidant Activity of BG-4
The antioxidant capacity of BG-4 was tested via the oxygen radical absorbance capacity assay
(ORAC) as described by Vernaza and coworkers [15] with slight modifications. In brief, 150 µL of
fluorescein solution prepared in phosphate buffer (75 mM, pH 7.4) were plated in a black 96-well
plate. Twenty-five microliters of Trolox standard curve (100–3.125 µM in phosphate buffer), blank or
sample diluted in phosphate buffer were added and incubated at 37 ◦ C for 30 min. Then, 25 µL of
2,20 -azobis (2-amidinopropane) dihydrochloride (AAPH) (Sigma-Aldrich, St. Louis, MO, USA) solution
at 41.5 mg/mL in phosphate buffer was added and fluorescence was read at 485 nm/20 nm excitation
and 528 nm/20 nm emission wavelengths for 2 h every min. Each sample and standard curve point
was measured in triplicate and results were expressed as µM of Trolox equivalents/g of BG-4. Radical
scavenging activity was measured by quantifying the inhibition of 2,2-diphenyl-1-picrylhydrazyl
free radical (DPPH•). Briefly, 100 µL of sample and blank were plated in a clear 96-well plate, then
100 µL of 100 µM DPPH• (Sigma-Aldrich, St. Louis, MO, USA) dissolved in methanol were added and
incubated in dark for 30 min. Simultaneously, a combination of sample and methanol, instead DPPH•,
were tested as reference for background signal. Absorbance was read at 517 nm. The absorbance
of methanol reference was subtracted and the percentage of inhibition was calculated against blank.
Results are presented as percentage of scavenging rate of DPPH•.
2.3. Measurement of Pro-Inflammatory Markers In Vitro
Murine RAW 264.7 macrophages were cultured in DMEM supplemented with 10% heat-inactivated
fetal bovine serum (Life Tech, Carlsbad, CA, USA) and 1% penicillin/streptomycin at 37 ◦ C in a
humidified 5% CO2 incubator. Cells were seeded at 2 × 105 cells/well in 6-well plates in 2 mL media,
or 5 × 103 cells/well in 96-well plates in 200 µL media and allowed to attach overnight. Cells were
treated with BG-4 (0–500 µg/mL) for 8 h and stimulated with LPS (1 µg/mL) for 16 h. After which,
supernatant was collected for TNF-α and IL-6 measurement via ELISA following the manufacturer’s
protocol (BioLegend, San Diego, CA) and nitric oxide (NO) production by Griess reagent assay.
Whole cell lysates were collected for immunoblotting of inducible nitric oxidase synthase (iNOS) and
cyclooxygenase-2 (COX-2) (ProteinTech, Chicago, IL, USA) by chemiluminescence following standard
protocol. Cell viability was tested by MTS assay following the manufacturer’s protocol (Promega,
Madison, WI, USA).
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2.4. Dosage Information and In Vivo Experimental Procedure
The BG-4 dose used in the animal study (15 mg/kg body weight (bw)) is equivalent to the
optimum concentration (375 µg/mL) of BG-4 in vitro producing significantly decreased expression of
pro-inflammatory markers without affecting cell viability. This translation assumes an average mouse
weight of 25 g and circulating blood of 1 mL. This will be equivalent to a daily intake of two 500 mg
capsules as a dietary supplement for a 70-kg person. The protocol for the animal experiment was
approved by the Institutional Animal Care and Use Committee of the University of Tennessee Knoxville
(Approval Protocol #2591-0418) and followed guidelines of the National Institutes of Health guide for
the care and use of Laboratory Animals (NIH Publications No. 8023, revised 1978). Twenty-two male
C57BL/6 7-week old mice (Jackson Laboratories, Harbor, ME, USA) were randomized and housed in
pairs in standard mouse cages with water and food provided ad libitum, under standard controlled
conditions (23 ± 2 ◦ C, 30–70% relative humidity with 12 h light and 12 h dark cycle). Mice were
randomly divided into three groups and treated as follows: control group (CG, n = 6), DSS-treated group
(DSS, n = 8), and DSS + BG-4-treated group (BG-4, n = 8). Mice in CG were administered with normal
drinking water, while DSS and BG-4 groups received drinking water with 3% DSS (MW = 36–50 kDa,
MP Biomedicals, Santa Ana, CA) to induce colitis. Two stages of DSS administration were performed
allowing a recovery period in between, in order to simulate the periods of relapse and remission that
IBD patients experience [16]. Daily intraperitoneal injection (IP) of 100 µL sterile water was performed
over CG and DSS groups, while BG-4 received IP of 15 mg BG-4/kg bw dissolved in 100 µL sterile
water. Food intake and body weight were recorded daily. Presence of visible blood (in stool or anus),
as well as stool consistency, were monitored and scored daily. Stool samples were collected from the
cages every three days to evaluate the presence of occult blood via quantification of hemoglobin in
feces. At day 15, mice were anesthetized with isoflurane, blood collected by cardiac puncture, followed
by cervical dislocation. Colon was removed, washed with PBS, length measured and cut longitudinally
into two pieces: one for hematoxylin and eosin (H&E) staining, and the other frozen in liquid nitrogen
for biochemical analysis.
2.5. Myeloperoxidase Assay in the Colon
Neutrophils infiltration was assessed by measuring myeloperoxidase (MPO) activity in colonic
extracts as reported previously [17] with slight modifications. Colonic extracts were obtained by beads
homogenization of 50 mg of colon samples with 1 mL buffer (5 g of hexadecyltrimethylammonium in
1 L of 50 mM potassium phosphate buffer at pH 6.0), followed by centrifugation at 20,000× g for 15 min
at 4 ◦ C. Supernatant was collected and further centrifuged to ensure total precipitation of solid tissue.
Ten µL of supernatant was plated in triplicate in a 96-well plate and combined with 200 µL freshly
prepared o-dianisidine solution (16.7 mg of o-dianisidine, 90 mL of deionized water and 10 mL of
potassium phosphate buffer, combined with 50 µL of 1.2% H2 O2 ). Absorbance at 450 nm was recorded
every 30 s for 5 min. MPO activity was calculated as the amount needed to degrade 1 µmol H2 O2 /min
at 21–22 ◦ C per mg protein in the colonic extract.
2.6. Measurement of Hemoglobin Content in the Feces
Presence of occult blood in the feces was assessed by measuring hemoglobin content [18,19].
Twenty mg of freeze-dried pulverized samples were vortexed with 100 µL dH2 O, and boiled for 10 min.
Six hundred microliters of 30% acetic acid was added, vortexed for 2 min, then 900 µL of ethyl acetate
was added, and organic layer was collected in a separate microcentrifuge tube after centrifugation at
2000× g for 3 min. In a quartz cuvette, equal parts of the organic phase and TMB solution (14.4 mg of
3,30 ,5,50 -tetramethylbenzidine in 100 mL mixture of glacial acetic acid/dH2 O/ethanol 20/30/50) were
mixed and the reaction was started by adding the same amount of 3% H2 O2 . The absorbance was
recorded at 660 nm at 30 s, 60 s, and 90 s. Hemoglobin content was calculated as the average for
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the three time points per mg of feces using bovine hemoglobin (Alfa Aesar, Ward Hill, MA, USA)
standard curve.
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Figure 2. Effect of BG-4 on viability of activated lipopolysaccharide (LPS+) and non-activated (LPS-)
Figure 2. Effect of BG-4 on viability of activated lipopolysaccharide (LPS+) and non-activated (LPS-)
macrophages (A), NO production (B), cytokine production (C), and iNOS and COX-2 expression (D),
macrophages (A), NO production (B), cytokine production (C), and iNOS and COX-2 expression (D),
in vitro. Results are presented as mean ± SD for (A–C) and mean ± SE for (D). Different letters indicate
in vitro. Results are presented as mean ± SD for (A), (B) and (C) and mean ± SE for (D). Different
significant differences (p < 0.05) among treatments.
letters indicate significant differences (p < 0.05) among treatments.
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killing, and can induce host tissue damage by promoting inflammation [31]. It is mainly present in
killing, and can induce host tissue damage by promoting inflammation [31]. It is mainly present in
specialized granules of neutrophils hence elevated MPO levels and neutrophil infiltration have been
specialized granules of neutrophils hence elevated MPO levels and neutrophil infiltration have been
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activity four and 14 times higher, respectively, than CG (Figure 4C), corroborating observations in H&E
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H&E staining micrographs where a higher infiltration of immune cells was detected for both groups
elevated severity upon BG-4 treatment.
with elevated severity upon BG-4 treatment.
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Figure 5. Effect of BG-4 on the level of pro-inflammatory cytokines in colonic extract (A) and serum
(B). Results are presented as mean ± SE. Different letters indicate significant differences (p < 0.05)
among treatments.
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Our results showed that BG-4 exerted a differential effect over inflammation in vitro and in vivo.
In LPS-stimulated macrophages, treatment with BG-4 showed a dose-dependent reduction of NO,
IL-6, COX-2, and iNOS, suggesting 375 µg/mL as an optimal concentration for significant reduction of
inflammatory markers. However, IP administration of BG-4 in a DSS-induced colitis mouse model,
aggravated disease symptoms when compared with untreated mice, accompanied by the dysregulation
of pro-inflammatory cytokines. The systemic circulation of BG-4 due to IP administration involved a
possible effect over other immune and epithelial cells that can be more or less sensitive, in terms of
cytotoxicity [34] and alteration of signaling and regulatory pathways, than the tested macrophages. For
instance, it has been recently demonstrated the induction of NO metabolism in enterocytes alleviates
colitis and CACC [29], suggesting a controversial role of NO in the regulation of the inflammatory
response associated with its origin. According to this perspective, suppression of NO production
exerted by BG-4 could result in a counteracting effect by simultaneously suppressing NO production
on macrophages and enterocytes.
The outcomes observed in vivo under BG-4 treatment suggest that the mechanistic effect by which
BG-4 suppresses NO production may be associated with enterocyte than macrophages. Under this
circumstance, the reduced expression of NO by the enterocyte allows neutrophils infiltration, generation
of cytotoxic compounds by MPO, tissue damage, and a consequently increased inflammatory response.
One strength of our study is the first report on the comparative anti-inflammatory properties of BG-4
peptide from Momordica charantia using both in vitro and in vivo models. In addition, both mouse cell
line and mouse model of colitis were utilized in the study. On the other hand, the observed contrasting
result of in vitro and in vivo models on the anti-inflammatory effect of BG-4 is a potential weakness.
The intraperitoneal injection of BG-4 may have resulted in the toxic effect of BG-4 in mouse model
resulting in its pro-inflammatory effect which is contradictory in the observed anti-inflammatory effect
in vitro. Hence the next step on the potential application of BG-4 for management of inflammatory
diseases must be observed via oral route to determine if it can be used as a dietary supplement to
mitigate diseases such as colitis.
4. Conclusions
In RAW 264.7 macrophages, BG-4 reduced the production of pro-inflammatory molecules NO,
IL-6 and TNF-α as well as the expression of COX-2 and iNOS. On the other hand, in DSS-induced
colitis mouse model intraperitoneal administration of BG-4 led to diarrhea, blood in stool and loss in
weight. Our results demonstrated that IP administration of BG-4 in DSS-induced colitis mouse model
led to a worsened outcome of the disease, in contrast to the reduction of the pro-inflammatory markers
observed in vitro. BG-4 dose and route of administration must be further studied to realize the role of
BG-4 in ameliorating IBD.
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